NEW YORK (GenomeWeb) – Biocartis reported today a 57 percent increase in revenues for the full year 2015.
The Belgian molecular diagnostics firm said that total revenues climbed to €13.3 million ($15.1 million) from €8.5 million in 2014. Collaboration revenue more than tripled to €9.7 million from €3.2 million a year ago. Product sales revenue dropped 32 percent to €3.6 million from €5.3 million in 2014.
In a statement accompanying the release of results, Biocartis said it added collaborations with Microbiome, Fast-track diagnostics, A*Star, Merck KGaA, and Amgen in 2015.